January 7, 2013
provides investors with quality research and analysis on U.S. equities on the move and today issues a report on:
TG Therapeutics Inc.
, MiMedx Group Inc.
, World Moto Inc.
, and USA Graphite Inc.
TG Therapeutics, Inc. (OTCBB: TGTX) announced FDA clearance to commence clinical trials of its novel, PI3K-Delta Specific Inhibitor, TGR-1202, under its recently filed U.S. Investigational New Drug (IND) Application.
, executive chairman and interim CEO, stated, "This is an exciting way to start the new year. TGR-1202 holds great promise and this is the first step to determining its true potential. We look forward to opening our first-in-human clinical trial as soon as possible. The great speed at which the team moved to achieve this milestone for TGR-1202 is extremely impressive considering our global development agreement was just recently executed in the 3
quarter of 2012. Our team is eager to continue this aggressive pace as we implement the clinical development program planned for TGR-1202."
TG Therapeutics, Inc. has gained 34% in just two days.
Read the entire press release issued by TG Therapeutics, Inc. (OTCBB: TGTX) here:
MiMedx Group, Inc. (OTCBB: MDXG) received an outperform rating from Northland Securities research firm. Northland Securities has just initiated coverage on the Company. MiMedx Group, Inc. has gained nearly 17% in one week.
Read the entire press release issued by MiMedx Group, Inc. (OTCBB: MDXG) here:
World Moto, Inc. (OTCBB: FARE) has attracted significant interest and coverage on its Moto-Meter in a number of publications and other media. Moto-Meter is the world's first motorcycle taxi meter.
Fast Company Magazine's
full article titled "Introducing the First Real Taxi Meter Innovation in 100 Years" refers to the Moto-Meter as "a
$3 billion dollar
idea... Meet the taxi meter that would take over the world... The market for the device is potentially enormous."
World Moto, Inc. has gained nearly 133% in the last two weeks.